Resistance train at least three times per week, eat 1.2 to 1.6 grams of protein per kilogram of body weight daily, and track your body composition — not just your scale weight — throughout treatment. Those three interventions are the difference between losing fat and losing the muscle that keeps your metabolism functional after you stop the medication. The data is unambiguous about the problem: depending on the study and measurement method, somewhere between 25% and 40% of weight lost on GLP-1 medications is lean mass rather than fat. In the SURMOUNT-1 DXA substudy, about 25% of weight lost on tirzepatide was lean mass [2], while STEP 1 DEXA data showed a higher proportion with semaglutide [1] — the variation reflects differences in populations, measurement timing, and methodology. Without targeted intervention, GLP-1 medications don't just shrink your fat stores — they erode the tissue that burns calories, stabilizes your joints, and determines whether you'll be physically capable at 70.

How Much Muscle Are You Actually Losing?

The numbers vary by study, medication, and how you measure — but the direction is consistent.

The BELIEVE trial, presented at the American Diabetes Association Scientific Sessions in 2025, found that semaglutide 2.4 mg alone produced a 15.7% body weight reduction but a 7.4% reduction in total body lean mass over 72 weeks [3]. Only 71.8% of the weight lost came from fat. The remaining 28.2% was lean tissue — muscle, water bound to muscle, connective tissue, and organ mass.

A case series published in PMC in 2025 reviewing lean mass preservation strategies noted that STEP 1 showed approximately 40% of weight loss was lean soft tissue (6.9 kg lean vs. 10.4 kg fat), while SURMOUNT-1 showed 26% lean soft tissue loss (5.6 kg lean vs. 15.9 kg fat) [4]. The variation between studies reflects differences in populations, measurement timing, and the distinction between tirzepatide and semaglutide — but across all the data, the pattern is clear: somewhere between a quarter and two-fifths of what you're losing isn't fat.

Research presented at ENDO 2025 by Dr. Melanie Haines of Harvard Medical School and Massachusetts General Hospital identified that within the semaglutide group, greater muscle loss was associated with older age, female sex, and lower protein consumption [3]. This isn't random attrition — it's predictable, and the risk factors tell you exactly where to intervene.

Why Lean Mass Loss Matters More Than You Think

Muscle isn't just about strength or appearance. It's the primary engine of your resting metabolic rate — the calories your body burns doing nothing. Lose significant muscle during GLP-1 treatment, and when you eventually reduce or stop the medication, your body is burning substantially fewer calories than before treatment began. Your appetite returns to pre-treatment levels, but your metabolic furnace has been downsized.

Researchers call the resulting pattern "collateral fattening" — weight regain that is almost mathematically inevitable because the metabolic equation has been tilted against you by the treatment itself. A patient who loses 40 pounds but 15 of those pounds were muscle has a lower resting metabolic rate, less glucose disposal capacity, and a worse metabolic starting position for maintenance than someone who lost the same 40 pounds but preserved lean tissue.

Beyond metabolism, the functional implications are significant:

• Muscle is responsible for most postprandial glucose disposal — the mechanism by which your body processes blood sugar after meals. Less muscle means worse blood sugar control, even at a lower body weight [3].
• Bone mineral density declines alongside lean mass. Preliminary, unpublished data presented by researchers from NewYork-Presbyterian/Weill Cornell suggested patients on incretin-based drugs lost about 10% in total hip BMD at 17 months — though this finding has not yet been peer-reviewed and should be interpreted cautiously [3]. Muscle and bone are physiologically linked — preserving one helps protect the other.
• Fall risk and frailty accelerate when lean mass drops below functional thresholds, particularly in adults over 50. Older adults already lose up to 8% of lean mass per decade starting around age 40 — adding GLP-1-driven muscle loss on top of that trajectory is compounding risk.

This is why "the scale went down" is an inadequate measure of treatment success. A provider who sees 20 pounds lost and calls it a win may be looking at a patient who lost 8 pounds of muscle and 12 pounds of fat — which is a metabolic problem, not a success.

The Three Pillars: Resistance Training, Protein, and Monitoring

Current evidence converges on three interventions that meaningfully reduce lean mass loss during GLP-1 therapy. None is optional. All three work together.

Pillar 1: Resistance Training

A Frontiers review of GLP-1 medications and exercise concluded that "resistance training, rather than aerobic exercise, attenuates lean body mass loss during weight-loss diets in adults with overweight or obesity" [5]. This is the single most effective non-pharmacological intervention for preserving muscle during weight loss.

What the evidence supports:

• Resistance training at least 3 times per week, targeting all major muscle groups
• 60-90 minutes total weekly resistance training volume
• Compound movements — squats, deadlifts, presses, rows, lunges — that load multiple muscle groups simultaneously
• Progressive overload — gradually increasing weight or resistance, not just repeating the same routine
• Supplemented by 150 minutes of moderate aerobic activity per week (walking, cycling, swimming)

What actually works in practice: The case series in PMC documented patients who successfully preserved lean mass with 3-5 days per week of resistance training at subjective intensity ratings of 7-8 out of 10, using bodyweight exercises, free weights, resistance bands, and kettlebells for 15-45 minutes per session [4]. One patient actually gained lean mass (+2.5%) while losing 26.8% body weight — and another gained 5.8% lean mass while losing 13.2% body weight. These results required consistent effort, but they prove that muscle preservation — and even growth — is achievable during GLP-1 treatment.

The critical insight: start resistance training from day one of GLP-1 treatment, not after you've already lost significant lean mass. Building the exercise habit while appetite suppression makes compliance easier is strategically important — by the time appetite returns during tapering, the habit is automatic.

Pillar 2: Protein Intake

A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society — published in 2025 — established that protein intake during active weight loss should be 1.2 g/kg to 1.6 g/kg of body weight daily, substantially above the general population recommendation of 0.8 g/kg [6]. Some researchers recommend even higher targets of 1.6-2.3 g/kg relative to fat-free mass during obesity treatment [4].

In practical terms:

• A 200-pound (91 kg) person needs approximately 109-146 grams of protein per day
• A 250-pound (113 kg) person needs approximately 136-181 grams per day
• A 160-pound (73 kg) person needs approximately 88-117 grams per day

This is genuinely difficult to achieve when GLP-1 medications are suppressing your appetite and reducing your total food intake. A patient eating 1,200 calories per day — common during active GLP-1 treatment — would need to derive 35-50% of those calories from protein to hit the lower end of the target. Without deliberate planning, most patients fall far short.

Protein-first eating — prioritizing protein at every meal before carbohydrates or fats — is the most practical strategy. This means eating the chicken before the rice, the eggs before the toast, the Greek yogurt before the fruit. When your appetite is limited, every bite needs to count toward the target.

Protein timing also matters: distributing intake across 3-4 meals rather than concentrating it in one sitting maximizes muscle protein synthesis. The body can only utilize a limited amount of protein per meal for muscle building — excess is oxidized for energy.

Pillar 3: Body Composition Monitoring

You cannot manage what you don't measure. A standard bathroom scale tells you total weight — it cannot distinguish between losing 15 pounds of fat and losing 10 pounds of fat plus 5 pounds of muscle. These are radically different clinical outcomes that require radically different responses.

Dr. Sangeeta Kashyap of NewYork-Presbyterian/Weill Cornell stated directly: "If we could measure body composition through the course of their treatment, it'd be great. But a lot of practitioners don't have access to measuring body composition or it's not covered by insurance, so that's not being done" [3].

This is one of the clearest gaps in GLP-1 care delivery. Body composition tracking — whether via InBody bioelectrical impedance, DXA scans, or even home bioimpedance scales — transforms the clinical conversation from guesswork to data. When you see lean mass declining disproportionately, you can intervene with increased protein, adjusted exercise, or medication modification before the damage is done.

JumpstartMD equips all 14 California locations with InBody body composition devices and tracks lean mass and fat mass as core clinical metrics — not just weight. The care team uses this data to detect disproportionate muscle loss early and intervene with adjusted protein targets, exercise strategies, or medication modifications. As their clinical materials state: "we track your muscle mass to protect it" and deliver "safe, muscle-protective weight loss." InBody scans are available anytime, not just at scheduled appointments, so the data flows continuously rather than appearing as a surprise at a quarterly check-in.

This matters because the typical telehealth GLP-1 prescription model has no body composition capability at all. A provider who never measures lean mass cannot detect that a patient is losing muscle at an unacceptable rate — and by the time the problem manifests as metabolic dysfunction or functional decline, the window for easy intervention has passed.

Who Faces the Highest Risk

Not all patients lose lean mass at the same rate. The evidence identifies specific populations where vigilance needs to be highest:

• Older adults (over 50) — age-related muscle loss (sarcopenia) is already progressing; GLP-1 medications accelerate it. Up to 8% of lean mass is lost per decade starting around age 40, and adding pharmacological weight loss compounds the trajectory [3].
• Women — the ENDO 2025 data showed female sex as an independent risk factor for greater lean mass loss on semaglutide [3]. Postmenopausal women face the additional intersection of declining estrogen (which protects both muscle and bone) and GLP-1-driven weight loss.
• Patients with low protein intake — directly correlated with greater muscle loss in the Harvard/MGH data [3]. If you're not eating enough protein before starting GLP-1 treatment, the deficit worsens when appetite suppression further reduces food intake.
• Sedentary patients — without resistance training stimulus, there is no physiological signal telling the body to preserve muscle during caloric deficit. The body treats unstimulated muscle as expendable.
• Patients with pre-existing frailty or chronic illness — any baseline functional limitation amplifies the impact of additional lean mass loss.

The Pharmacological Pipeline: Muscle-Preserving Add-Ons

The pharmaceutical industry has recognized lean mass loss as a clinical problem worth solving. Several drugs are in development that aim to preserve or increase muscle while augmenting GLP-1-driven fat loss.

Bimagrumab (Eli Lilly), a monoclonal antibody targeting the activin type II receptor, showed the most striking results to date. In the BELIEVE trial, combination bimagrumab plus semaglutide 2.4 mg produced 22.1% weight loss with only a 2.9% reduction in lean mass — compared to 7.4% lean mass loss with semaglutide alone [3]. Bimagrumab alone actually increased lean mass by 2.5% while producing 10.8% weight loss, with 100% of weight loss coming from fat.

Trevogrumab (Regeneron), which targets myostatin, showed lean mass loss of 3.3% versus 6.5% with semaglutide alone at 26 weeks. Apitegromab (Scholar Rock), another myostatin inhibitor combined with tirzepatide, preserved an additional 4.2 pounds of lean mass versus tirzepatide alone.

These drugs are still in clinical trials. None is available yet. But they validate the clinical reality: lean mass loss during GLP-1 therapy is a recognized problem significant enough to justify dedicated pharmacological intervention. Until these medications become available, resistance training and protein remain the frontline defense.

What Your Provider Should Be Doing

A comprehensive GLP-1 program should treat muscle preservation as a core clinical objective — not an afterthought mentioned in a pamphlet.

JumpstartMD builds this into the clinical framework from the first appointment. Body composition analysis via InBody scanning establishes a baseline before treatment begins. Protein targets are set individually based on body composition data, medication, age, weight, and activity level. When clinically indicated, therapeutic amino acid supplementation is available on-site to address deficiencies that dietary intake alone may not correct during the most appetite-suppressed phases of treatment. And when GLP-1 medications cause muscle loss, the team helps "preserve and rebuild lean mass with hormone support, evidence-based supplements like creatine, and lifestyle coaching — because it's not just about losing pounds. It's about losing the right pounds."

The four-phase exit protocol — Stabilization, Metabolic Hardening, Taper, Bridge — specifically addresses lean mass in Phase 2, where the clinical focus shifts entirely to body composition before any medication reduction begins. The goal is to raise resting metabolic rate as high as possible before the medication is tapered — building the metabolic foundation that sustains results independently.

If you want to ensure that muscle preservation is part of your GLP-1 treatment plan from the start — not discovered as a problem after the damage is done — call 408.478.3496.

Frequently Asked Questions

Q: How much muscle do you lose on semaglutide? A: Studies show that 25-40% of total weight lost on GLP-1 medications is lean mass rather than fat, depending on the study, population, and measurement method. In SURMOUNT-1, about 25% of weight loss on tirzepatide was lean mass [2], while STEP 1 showed a higher proportion with semaglutide [1]. With targeted resistance training and adequate protein intake, these proportions can be dramatically reduced — published case reports show patients achieving less than 9% lean mass loss, or even gaining lean mass, during GLP-1 treatment [4].

Q: How much protein should I eat on a GLP-1 medication? A: A 2025 joint advisory from four major medical organizations recommends 1.2 to 1.6 grams of protein per kilogram of body weight daily during active weight loss [6]. For a 200-pound person, that's approximately 109-146 grams per day. Prioritize protein at every meal, distribute intake across 3-4 eating occasions, and consider protein supplementation if appetite suppression makes food-based targets impossible to reach.

Q: Is cardio or weight training better for preventing muscle loss? A: Resistance training. A Frontiers review found that resistance training, not aerobic exercise, is what attenuates lean body mass loss during weight loss [5]. Cardio has important cardiovascular benefits and should be part of your routine (150 minutes per week of moderate activity), but it does not provide the muscle-preserving stimulus that resistance training does. Aim for at least three resistance sessions per week targeting all major muscle groups.

Q: Should I start exercising before or after starting the GLP-1? A: Before or simultaneously — not after. Starting resistance training from day one of treatment establishes the habit during the period when appetite suppression makes compliance easiest. More importantly, it sends the physiological signal to preserve muscle from the very beginning of caloric restriction, rather than trying to rebuild lost tissue later.

Q: How do I know if I'm losing too much muscle? A: You need body composition data — a bathroom scale cannot tell you. InBody scans, DXA scans, or bioimpedance devices distinguish fat loss from lean loss. Warning signs without data include increasing fatigue despite adequate sleep, declining strength in exercises you previously handled, difficulty with stairs or standing from a chair, and feeling cold more easily (lower metabolic rate). If you notice these, talk to your provider about body composition testing.

Q: Does JumpstartMD monitor body composition during GLP-1 treatment? A: Yes. JumpstartMD tracks lean mass and fat mass using InBody devices at all 14 California locations. Scans are available anytime, and the clinical team uses body composition data — not just scale weight — to detect disproportionate muscle loss and intervene with adjusted protein targets, exercise strategies, supplementation, or medication modifications. Call 408.478.3496 to learn more.

Conclusion

Preventing muscle loss on GLP-1 medications requires three concurrent interventions: resistance training at least three times per week, protein intake of 1.2-1.6 g/kg daily, and regular body composition monitoring that goes beyond scale weight [4][5][6]. The data shows that 25-40% of weight lost on these medications can be lean tissue rather than fat, depending on the study and population [1][2], but patients who combine structured resistance training with adequate protein can reduce lean mass loss to single digits — or even gain muscle during treatment [4]. The distinction between losing fat and losing muscle is the distinction between treatment that sets you up for lasting results and treatment that sets you up for metabolic rebound. Make sure your provider is measuring the difference.

References

[1] J. P. H. Wilding et al., "Once-weekly semaglutide in adults with overweight or obesity," New England Journal of Medicine, vol. 384, no. 11, pp. 989-1002, 2021. [Accessed: Feb. 11, 2026].

[2] A. M. Jastreboff et al., "Tirzepatide once weekly for the treatment of obesity," New England Journal of Medicine, vol. 387, no. 3, pp. 205-216, 2022. [Accessed: Feb. 11, 2026].

[3] M. Monostra, "'Muscle matters': The challenge of preserving lean mass during obesity treatment," Healio Endocrine Today, Nov. 2025. [Accessed: Feb. 11, 2026].

[4] "Preservation of lean soft tissue during weight loss induced by GLP-1 receptor agonists," PMC, 2025. [Accessed: Feb. 11, 2026].

[5] "GLP-1 agonists and exercise: the future of lifestyle prioritization," Frontiers in Clinical Diabetes and Healthcare, 2025. [Accessed: Feb. 11, 2026].

[6] D. Mozaffarian et al., "Nutritional considerations for adults using incretin-based medications for overweight and obesity: a joint advisory," American Journal of Clinical Nutrition, 2025. [Accessed: Feb. 11, 2026].